The US federal government is now left with 63 million doses of the antimalarial drug hydroxychloroquine sulfate (HCQ) in its Strategic National Stockpile after the US Food and Drug Administration (FDA) on Monday revoked permission for the drug to be used for COVID-19 treatment.
In addition to HCQ, the FDA also revoked its authorization of the use of chloroquine phosphate (CQ), which can also treat and prevent malaria, for COVID-19 treatment.
The FDA’s EUA applied only to hospitalized COVID-19 patients and to drugs in the Strategic National Stockpile, so individual doctors are still able to prescribe HCQ off-label, since it has been approved for other uses.
The US government began stockpiling HCQ in late March, after the FDA authorized hospitals to use the drug to treat patients who had contracted the novel coronavirus. The drug has also been touted by US President Donald Trump, who took it himself to prevent COVID-19 infection despite the FDA’s warnings that the drug can cause heart problems.
Some experts have expressed regret that so much emphasis was placed on HCQ for COVID-19 treatment.
In a statement to CNN, Carol Danko, a US Department of Health and Human Services (HHS) spokesperson, revealed that the HHS is now collaborating with companies who donated the drugs to “determine the available options for the product.” Around 31 million doses were distributed from the stockpile before the FDA revoked its authorization Monday. Along with the 63 million HCQ doses, the stockpile currently contains about 2 million doses of CQ, Danko noted.
In a statement Wednesday, the World Health Organization (WHO) said that recent findings show that the drug does not reduce mortality of “hospitalized COVID-19 patients” and that it will thus halt all studies regarding the drug.
So far, two drugs, namely remdesivir and dexamethasone, have shown promising trial results in helping hospitalized COVID-19 patients recover faster and preventing death from the respiratory disease.